Effects of CB2 and TRPV1 Stimulation on Osteoclast Overactivity Induced by Iron in Pediatric Inflammatory Bowel Disease

Overview

Journal Inflamm Bowel Dis

Publisher Oxford University Press

Specialty Gastroenterology

Date 2022 Apr 26

PMID 35472140

Authors

Chiara Tortora

Alessandra Di Paola

Mara Creoli

Maura Argenziano

Massimo Martinelli

Erasmo Miele

Francesca Rossi

Caterina Strisciuglio

Affiliations

Soon will be listed here.

Abstract

Background: The reduction of bone mineral density and osteoporosis have high impacts on the health of patients with inflammatory bowel diseases (IBD). We have previously shown that a dysregulated iron metabolism occurs in IBD and leads to a decrease in circulating iron concentration and excessive intracellular sequestration of iron. Studies suggest that iron overload significantly affects the bone, accelerating osteoclast (OC) differentiation and activation, promoting bone resorption. Moreover, we demonstrated that iron overload causes OC overactivity. The cannabinoid receptor type 2 (CB2) and the transient receptor potential vanilloid type-1 (TRPV1) are potential therapeutic targets for bone diseases. The aim of this study was to evaluate the roles of CB2 and TRPV1 receptors and of iron in the development of osteoporosis in pediatric IBD.

Methods: We differentiated OCs from peripheral blood mononuclear cells of patients with IBD and healthy donors and evaluated CB2 and TRPV1 receptor expression; OC activity, and iron metabolism by Western blot, TRAP assays, bone resorption assays, and iron assays. Moreover, we analyzed the effects of the pharmacological modulation of CB2 and TRPV1 receptors on OC activity and on the iron metabolism.

Results: We confirmed the well-known roles of CB2 and TRPV1 receptors in bone metabolism and suggested that their stimulation can reduce the OC overactivity induced by iron, providing new insights into the pathogenesis of pediatric IBD-related bone resorption.

Conclusions: Stimulation of CB2 and TRPV1 could reduce IBD-related osteoporosis due to their direct effects on OC activity and to modulating the iron metabolism.

Citing Articles

Cannabinoid Receptor Type 2 Agonist, GW405833, Reduced the Impacts of MDA-MB-231 Breast Cancer Cells on Bone Cells.

Inson I, Chutoe C, Kanjanapipak J, Lertsuwan K Cancer Med. 2025; 14(4):e70709.

PMID: 39980332 PMC: 11842928. DOI: 10.1002/cam4.70709.

TRPV1 Regulates Proinflammatory Properties of M1 Macrophages in Periodontitis Via NRF2.

Li Y, Guo X, Zhan P, Huang S, Chen J, Zhou Y Inflammation. 2024; 47(6):2041-2056.

PMID: 38700791 DOI: 10.1007/s10753-024-02024-3.

Role of Iron Accumulation in Osteoporosis and the Underlying Mechanisms.

Li G, Gao Y, Weinberg E, Huang X, Xu Y Curr Med Sci. 2023; 43(4):647-654.

PMID: 37326889 DOI: 10.1007/s11596-023-2764-z.

CB2 Receptor as Emerging Anti-Inflammatory Target in Duchenne Muscular Dystrophy.

Argenziano M, Pota V, Di Paola A, Tortora C, Marrapodi M, Giliberti G Int J Mol Sci. 2023; 24(4).

PMID: 36834757 PMC: 9964283. DOI: 10.3390/ijms24043345.

Emerging Roles of the Iron Chelators in Inflammation.

Di Paola A, Tortora C, Argenziano M, Marrapodi M, Rossi F Int J Mol Sci. 2022; 23(14).

PMID: 35887336 PMC: 9318075. DOI: 10.3390/ijms23147977.

References

Dragoni G, Innocenti T, Galli A . Biomarkers of Inflammation in Inflammatory Bowel Disease: How Long before Abandoning Single-Marker Approaches?. Dig Dis. 2020; 39(3):190-203. DOI: 10.1159/000511641. View

Czuba L, Hillgren K, Swaan P . Post-translational modifications of transporters. Pharmacol Ther. 2018; 192:88-99. PMC: 6263853. DOI: 10.1016/j.pharmthera.2018.06.013. View

Sgambato D, Gimigliano F, De Musis C, Moretti A, Toro G, Ferrante E . Bone alterations in inflammatory bowel diseases. World J Clin Cases. 2019; 7(15):1908-1925. PMC: 6695530. DOI: 10.12998/wjcc.v7.i15.1908. View

Nso N, Nyabera A, Nassar M, Alshamam M, Sumbly V, Vest M . Cannabis and Its Potential Protective Role Against Inflammatory Bowel Disease: A Scoping Review. Cureus. 2021; 13(10):e18841. PMC: 8597664. DOI: 10.7759/cureus.18841. View

Che J, Yang J, Zhao B, Zhang G, Wang L, Peng S . The Effect of Abnormal Iron Metabolism on Osteoporosis. Biol Trace Elem Res. 2019; 195(2):353-365. DOI: 10.1007/s12011-019-01867-4. View

Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K . Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A. 2006; 103(3):696-701. PMC: 1334629. DOI: 10.1073/pnas.0504187103. View

Stojkovic Lalosevic M, Toncev L, Stankovic S, Dragasevic S, Stojkovic S, Jovicic I . Hepcidin Is a Reliable Marker of Iron Deficiency Anemia in Newly Diagnosed Patients with Inflammatory Bowel Disease. Dis Markers. 2020; 2020:8523205. PMC: 7737436. DOI: 10.1155/2020/8523205. View

Strisciuglio C, Bellini G, Miele E, Martinelli M, Cenni S, Tortora C . Cannabinoid Receptor 2 Functional Variant Contributes to the Risk for Pediatric Inflammatory Bowel Disease. J Clin Gastroenterol. 2016; 52(5):e37-e43. DOI: 10.1097/MCG.0000000000000755. View

Alcantara O, Reddy S, Roodman G, Boldt D . Transcriptional regulation of the tartrate-resistant acid phosphatase (TRAP) gene by iron. Biochem J. 1994; 298 ( Pt 2):421-5. PMC: 1137957. DOI: 10.1042/bj2980421. View

10.

Bab I, Ofek O, Tam J, Rehnelt J, Zimmer A . Endocannabinoids and the regulation of bone metabolism. J Neuroendocrinol. 2008; 20 Suppl 1:69-74. DOI: 10.1111/j.1365-2826.2008.01675.x. View

11.

Rossi F, Bellini G, Tolone C, Luongo L, Mancusi S, Papparella A . The cannabinoid receptor type 2 Q63R variant increases the risk of celiac disease: implication for a novel molecular biomarker and future therapeutic intervention. Pharmacol Res. 2012; 66(1):88-94. DOI: 10.1016/j.phrs.2012.03.011. View

12.

Isaacs J, Harari O, Kobold U, Lee J, Bernasconi C . Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis. Arthritis Res Ther. 2013; 15(6):R204. PMC: 3978585. DOI: 10.1186/ar4397. View

13.

Ledesma-Colunga M, Baschant U, Fiedler I, Busse B, Hofbauer L, Muckenthaler M . Disruption of the hepcidin/ferroportin regulatory circuitry causes low axial bone mass in mice. Bone. 2020; 137:115400. DOI: 10.1016/j.bone.2020.115400. View

14.

Oudit G, Trivieri M, Khaper N, Liu P, Backx P . Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy. J Mol Med (Berl). 2006; 84(5):349-64. PMC: 7095819. DOI: 10.1007/s00109-005-0029-x. View

15.

Xie W, Lorenz S, Dolder S, Hofstetter W . Extracellular Iron is a Modulator of the Differentiation of Osteoclast Lineage Cells. Calcif Tissue Int. 2015; 98(3):275-83. DOI: 10.1007/s00223-015-0087-1. View

16.

Basseri R, Nemeth E, Vassilaki M, Basseri B, Enayati P, Shaye O . Hepcidin is a key mediator of anemia of inflammation in Crohn's disease. J Crohns Colitis. 2012; 7(8):e286-91. DOI: 10.1016/j.crohns.2012.10.013. View

17.

Nasser Y, Woo M, Andrews C . Cannabis in Gastroenterology: Watch Your Head! A Review of Use in Inflammatory Bowel Disease, Functional Gut Disorders, and Gut-Related Adverse Effects. Curr Treat Options Gastroenterol. 2020; 18(4):519-530. PMC: 7680210. DOI: 10.1007/s11938-020-00323-w. View

18.

Du Q, Liao Q, Chen C, Yang X, Xie R, Xu J . The Role of Transient Receptor Potential Vanilloid 1 in Common Diseases of the Digestive Tract and the Cardiovascular and Respiratory System. Front Physiol. 2019; 10:1064. PMC: 6712094. DOI: 10.3389/fphys.2019.01064. View

19.

Wang L, Trebicka E, Fu Y, Ellenbogen S, Hong C, Babitt J . The bone morphogenetic protein-hepcidin axis as a therapeutic target in inflammatory bowel disease. Inflamm Bowel Dis. 2011; 18(1):112-9. PMC: 3139830. DOI: 10.1002/ibd.21675. View

20.

Buckley M, Kumar A, Swaminath A . Inflammatory Bowel Disease and Cannabis: A Practical Approach for Clinicians. Adv Ther. 2021; 38(7):4152-4161. PMC: 8279986. DOI: 10.1007/s12325-021-01805-8. View